Last Updated: 27/10/2016

Repeat Ivermectin Mass Drug Administrations for Control of Malaria (RIMDAMAL)

Objectives

*Alternative title: Dry-to-rainy Season Integrated Control of NTDs and Malaria

The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three-week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.

Principal Institution

Colorado State University

Principal Investigators / Focal Persons

Brian Foy

Rationale and Abstract

Repeated Ivermectin Mass Drug Administration (MDA) starting at the beginning of the rainy season will be well tolerated and safe and will reduce clinical malaria episodes in children by significantly reducing malaria transmission among treated villages.

Single-blind (outcomes assessor); parallel assignment with 2 arms; cluster-randomized control trial to determine the effect of repeated IVM MDA on malaria transmission and clinical malaria episodes.

The unit of randomization will be the village (cluster). 8 villages total will be enrolled in two arms. The active comparator arm (4 villages) will receive a single standard MDA (IVM; 150-200 µg/kg + albendazole; 400 mg) soon after the start of the rainy season, while the experimental arm (4 villages) will receive the standard MDA on the same date, plus 5 more IVM MDA at 3 week intervals thereafter.

Dose (ivermectin): 150 µg/kg

Outcome measures:

  • Primary outcome: Incidence of Clinical Malaria Episodes  (timeframe approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the experimental arm)
  • Secondary outcomes: adverse events, entomological indicator of parasite transmission, molecular force of P. falciparum infection, number of 6-10 year old participants with soil-transmitted helminths and entomological inoculation rate.
Study Design

 ClinicalTrials.gov Identifier: NCT02509481

Study Type  : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Date

Jan 2014 — Apr 2016

Total Project Funding

$100,000

Funding Details
Bill & Melinda Gates Foundation (BMGF)

Grand Challenges Explorations, Round 13
Project Site

Burkina Faso

SHARE

Related Resources

Related Projects

SHARE